Work

Case Report: Prolonged survival with short-course triplet induction and dual maintenance in recurrent/metastatic cervical cancer

Year: 2026

Type: article

Abstract: The median overall survival (OS) for patients with recurrent or metastatic cervical cancer after progression on first-line therapy is only 5-12 months. We retrospectively reviewed four patients who received modified induction-maintenance therapy. All of the patients achieved clinical benefit to varying degrees, with one attaining progression-free survival (PFS) of over 58 months and an OS of 86 months. However, these findings should be interpreted with caution and warrant validation in larger prospective studies.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2026.1961384

Authors: Yiqing Duan, Dan Liu, Qian Huang, Jianghan Man, Li Li, Yuanbo Xue

Institutions: Kunming Medical University, Peking University Cancer Hospital

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801